4.7 Article

The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis

期刊

ANNALS OF THE RHEUMATIC DISEASES
卷 70, 期 7, 页码 1320-1326

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/ard.2010.148296

关键词

-

资金

  1. Interdisciplinary Center of Clinical Research (IZKF) in Erlangen [A40]
  2. Deutsche Forschungsgesellschaft [00000023728]
  3. Medicine of the Ernst Jung Foundation

向作者/读者索取更多资源

Objectives Transforming growth factor beta (TGF beta) has been identified as a key player in fibrotic diseases. However, the molecular mechanisms by which TGF beta activates fibroblasts are incompletely understood. Here, the role of JunD, a member of the activator protein 1 (AP-1) family of transcription factors, as a downstream mediator of TGF beta signalling in systemic sclerosis (SSc), was investigated. Methods The expression of JunD was analysed by real-time PCR, immunofluorescence, western blotting and immunohistochemistry. The canonical Smad pathway was specifically targeted by small interfering (si) RNA. The expression of extracellular matrix proteins in JunD deficient (JunD(-/-)) fibroblasts was analysed by real-time PCR and hydroxyproline assays. The mouse model of bleomycin-induced dermal fibrosis was used to assess the role of JunD in experimental fibrosis. Results JunD was overexpressed in SSc skin and in cultured fibroblasts in a TGF beta dependent manner. The expression of JunD colocalised with pSmad 3 in fibrotic skin and silencing of Smad 3 or Smad 4 by siRNA prevented the induction of JunD by TGF beta. JunD(-/-) fibroblasts were less responsive to TGF beta and released less collagen upon stimulation with TGF beta. Moreover, JunD(-/-) mice were protected from bleomycin-induced fibrosis with reduced dermal thickening, decreased myofibroblast counts and lower collagen content of lesional skin. Conclusions These data demonstrate that JunD is overexpressed in SSc and that JunD is a mediator of the profibrotic effects of TGF beta. Considering that inhibitors of AP-1 signalling have recently been developed and are available for clinical trials in SSc, these findings may have translational implications.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据